-
German HTA Outcomes for Rare Disease Drugs When Orphan Designation Does Not Legally Determine Added Benefit
Sep 9, 2025, 16:22 PM -
Will Patient Input Shape EU-Level Health Technology Assessments? HTA Representative Perspectives on the EU HTA Regulation
Sep 9, 2025, 16:22 PM -
Assessment of Severity Modifiers vs. End-of-Life Criteria in Oncology
Sep 9, 2025, 16:22 PM -
Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in France: A Use Case in Rare Diseases
Sep 9, 2025, 16:22 PM -
Increased Trends of Self-Optimized Submissions to NICE
Sep 9, 2025, 16:22 PM -
Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology
Sep 9, 2025, 16:22 PM -
Danicopan: A Dominant Option for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Residual Hemolytic Anemia in Spain
Sep 9, 2025, 16:22 PM -
Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk
Sep 9, 2025, 16:22 PM -
Impact of Maternal Vaccination Strategy on RSV-Related Hospital Burden Among Infants Aged Less Than One Year in France: A Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Unlocking Access: Overcoming Barriers and Harnessing Enablers for Innovative Payment Models for Pharmaceutical Innovation in Europe
Sep 9, 2025, 16:22 PM -
Economic Value of Dupilumab in Preventing and Treating Comorbid Asthma in Pediatric Patients With Atopic Dermatitis: A Cost-Offset Model From the Italian Payer Perspective
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece
Sep 9, 2025, 16:22 PM -
Role of Technical Engagement in NICE Process Under Proportionate Approach to Technology Appraisals
Sep 9, 2025, 16:22 PM -
Developing the Next Generation of Therapeutics: The Role of Early Model-Based Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Comparison EQ-5D-Y-3L Responses Between Child Self-Reports and Caregiver Proxy Reports
Sep 9, 2025, 16:22 PM -
A Gap Analysis of HTA Methods in Europe: Results From SUSTAIN-HTA
Sep 9, 2025, 16:22 PM -
Demonstrating the Importance of Modeling Rapid Cancer Progression in Screening Evaluations
Sep 9, 2025, 16:22 PM -
Characterizing Medicines Reimbursed Under Managed Access Protocols in Ireland (2006-2025)
Sep 9, 2025, 16:22 PM -
Can We Quantify the Financial Impact of Patient-Reported Outcomes on the Value of Oncology Products?
Sep 9, 2025, 16:22 PM -
Informing Value-Based Pricing: Cost-Effectiveness Analysis of a Hypothetical First-Line Therapy for Metastatic Pancreatic Cancer
Sep 9, 2025, 16:22 PM
